Biography

Dr. Shyam Sundar Nandi

Designation: Scientist E/ Deputy Director
Division: Biotechnology, NIV Mumbai Unit
Contact:

• Mobile: +91-9082553865
• Office: +91 22 24134130 (Extn 721)
• Email: nandibiotech@gmail.com, drshyamnandi.icmr@gmail.com, shyam.nandi@gov.in
  Office: ICMR-National Institute of Virology, Mumbai Unit, Haffkine Institute Compound, A.D. Marg, Parel, Mumbai-12

Biography:
Dr. Shyam Sundar Nandi is a distinguished scientist and Deputy Director at the Biotechnology Division of ICMR-National Institute of Virology (NIV), Mumbai Unit. He commenced his journey with NIV on 14th November 2008, and has since made significant contributions to the field of biotechnology and molecular virology.

Educational Qualifications:

• Ph.D. in Biotechnology from Guru Ghasidas University, Bilaspur (C.G.)
• Post-Doctoral Research in Genomics and Genome Editing Technologies (CRISPR Cas9) from the University of Illinois at Chicago, USA
• M.Sc. in Biotechnology from Guru Ghasidas University, Bilaspur (C.G.)
• B.Sc. in Zoology, Chemistry, and Fishery from Vidyasagar University, Midnapore, West Bengal

Employment History:

• Scientist-E, ICMR-National Institute of Virology, Mumbai Unit (1st September 2021 - Present)
• Scientist-D, ICMR-National Institute of Virology, Mumbai Unit (1st September 2017 - 31st August 2021)
• Scientist-C, ICMR-Enterovirus Research Centre, Mumbai (1st September 2013 - 31st August 2017)
• Scientist-B, ICMR-Enterovirus Research Centre, Mumbai (14th November 2008 - 31st August 2013)

Awards and Honors:
Dr. Nandi's exemplary contributions have been recognized through numerous awards and honors, including the Best Innovation Award, Best Technology Innovation Award, Super 100 Award, and the Dr. Kalyan Banerjee's 85th Birth Anniversary Memorial Award.

Significant Contributions:

• Development of recombinant therapeutic protein hGCSF for neutropenia
• Identification of nucleotide substitutions at attenuation sites in Sabin OPV virus isolates
• Development of poliovirus non-permissive cell lines using CRISPR/Cas9 technology
• Creation of genetically tailored organotypic models for studying enteroviruses
• Design and development of point-of-care devices for Silicosis/Silico Tuberculosis
• Establishment of LAMP assays for the detection of SARS-CoV2, C. diphtheriae, Nipah virus, and Monkeypox virus
• Commercialization of kits for Silicosis/Silico Tuberculosis, poliovirus non-permissive cell lines, and LAMP kits for SARS-CoV2 detection

Dr. Shyam Sundar Nandi's relentless pursuit of scientific excellence and innovative research methodologies continue to inspire the scientific community towards advancements in virology and biotechnology.

Research Interest

Dr. Nandi's research interests primarily lie in the application of biotechnology to study enteroviruses, molecular virology, genomics/genome engineering, and the development of new vaccines and diagnostic assays. He is particularly focused on leveraging CRISPR Cas9 technology for engineering cell strains and studying enteroviruses and SARS-CoV-2.